Medical

Pfizer's New Treatment Elranatamab Receives FDA Breakthrough Therapy Designation For Relapsed Or Refractory Multiple Myeloma

Pfizer's new treatment, Elranatamab, has received Breakthrough Therapy designation from the FDA for the treatment of patients with relapsed or refractory multiple myeloma. Data from the trial showed a patient efficacy rate of 61.0% and that once the therapy is effective, efficacy is maintained for more than six months in over 90% of patients!

Medical

New Targeted Radiotherapy For "Laser-Like" Precision Treatment Of Refractory Prostate Cancer With Fewer Side Effects!

Prostate cancer, which has been increasing in incidence worldwide in recent years, is now a more common cancer among Japanese men. Often, patients with prostate cancer have a poor prognosis and poor survival once they have developed multiple recurrent metastases after treatment with hormones and are difficult to treat with conventional radiotherapy.

Medical

Significant Improvement In Survival For Pancreatic Cancer Patients! A first-Line NALIRIFOX Regimen To Look Forward To!

As medicine continues to advance, there are many good drugs and options to fight cancer. Just recently, a study showed that the NALIRIFOX regimen significantly improved the overall survival of patients with advanced pancreatic ductal adenocarcinoma who had not received previous treatment.

Disease

Clinical Trial Treatment Restores Health To Rare Uterine Cancer Patient

The trial is testing the effectiveness of two chemotherapy drugs, oxaliplatin and gemcitabine, in combination with radiotherapy, an approach that has been used to treat other aggressive tumours

Apparatus

Significantly Longer Survival In Refractory Breast Cancer With The Addition Of Eganelisib To Standard Treatment!

Data from a trial show that adding the new drug Eganelisib to standard treatment significantly improves the length of survival for patients with triple-negative breast cancer whose disease remains unexacerbated. Patients benefited regardless of their PD-L1 status.

Medical

New Technology Can Break The Blood-Brain Barrier To Directly Treat Brain Tumours, Is Potent And Less Toxic, And Deserves Attention!

For brain cancer, the major obstacle to treatment is not the tumour, but the brain itself. How to break the "blood-brain barrier" and allow effective anti-cancer drugs to enter the brain to take effect has long been a key issue in brain cancer treatment. Recently, a new study has shown that a new type of pump can be implanted in brain cancer patients to safely break the blood-brain barrier and better treat brain cancer!

Disease

How Is Bile Duct Cancer Caused? How Does Bile Duct Cancer Need To Be Treated?

Every disease has a cause, and we are all sick because of various factors. Understanding the causes of diseases can help us to prevent them, which will help our health a lot.

Disease

Prevention of cardiovascular disease is more important than treatment

Almost everyone hopes to have a young and healthy heart. However, 62% of people over 40 years old have cardiovascular disease or risk factors to varying degrees, and 80% of them have not yet fully understood how to maintain a healthy heart. Medical research shows that among all internal organs, the heart is most likely to suffer from "obesity", especially in patients with hypertension, which can also lead to gradual thickening of the heart muscle.

Healthy

Can People With a Weak Stomach Eat Roughage?

People with a weak stomach need to pay a little attention to their diet. Perhaps many people are unaware of what ingredients are specifically available in coarse grains, so today we will tell you what coarse grains are, and whether people with a bad stomach can eat them.

Medical

Standard Chemotherapy + Mitazalimab, More Than 90% Effective In The Treatment Of Pancreatic Cancer!

Pancreatic cancer has long been known as the "king of cancers" due to its poor prognosis. However, a recent study showed that adding Mitazalimab to a modified FOLFIRINOX regimen resulted in control of over 90% of patients with metastatic pancreatic cancer, with 52% of patients experiencing significant tumour shrinkage!